Adminstration USFaD. CERIANNA™ (fluoroestradiol F 18) Injection, for intravenous use, Reference ID 4610145. In. Edited by Administration USFaD: FDA; 2020.

Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER + breast Cancer. Clin Cancer Res. 2017;23(2):407–15.

Article  CAS  PubMed  Google Scholar 

Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol. 2011;38(7):969–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24(18):2793–9.

Article  CAS  PubMed  Google Scholar 

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, et al. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol. 2014;16(3):431–40.

Article  CAS  PubMed  Google Scholar 

Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, Lee SJ, Kim HJ, Ko BS, Lee JW, et al. Diagnostic accuracy and safety of 16α. -[Lancet Oncol. 2019;20(4):546–55.

Article  CAS  PubMed  Google Scholar 

(EBCTCG) EBCTCg. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139–50.

Article  Google Scholar 

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.

Article  CAS  PubMed  Google Scholar 

Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast. 2012;21(1):27–33.

Article  CAS  PubMed  Google Scholar 

Hua X, Bi XW, Zhao JL, Shi YX, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line treatment for patients with hormone receptor-positive and HER2-Positive metastatic breast Cancer (SYSUCC-002). Clin Cancer Res. 2022;28(4):637–45.

Article  CAS  PubMed  Google Scholar 

Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12):926–35.

Article  CAS  PubMed  Google Scholar 

Witters L, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep. 2002;9(6):1163–6.

CAS  PubMed  Google Scholar 

Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, et al. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev. 2015;41(2):69–76.

Article  CAS  PubMed  Google Scholar 

Dieci MV, Guarneri V. Should triple-positive breast cancer be recognized as a distinct subtype? Expert Rev Anticancer Ther. 2020;20(12):1011–4.

Article  CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med. 2022;387(1):9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nahta R, O’Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat. 2012;135(1):39–48.

Article  CAS  PubMed  Google Scholar 

Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, et al. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Res Treat. 2014;147(3):599–607.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

Article  Google Scholar 

Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, et al. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014;145(3):615–23.

Article  CAS  PubMed  Google Scholar 

Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol. 2008;216(4):399–407.

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–22.

Article  CAS  PubMed  Google Scholar 

Bruce S, Possolo A, Watters R. Metrological traceability frequently asked questions and NIST Policy, technical note (NIST TN). In. Gaithersburg, MD: National Institute of Standards and Technology; 2021.

Google Scholar 

Byrd DW, Doot RK, Allberg KC, MacDonald LR, McDougald WA, Elston BF, Linden HM, Kinahan PE. Evaluation of Cross-calibrated. Tomography. 2016;2(4):353–60.

Article  PubMed  PubMed Central  Google Scholar 

Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Mankoff DA, Linden HM, et al. Test-retest reproducibility of. J Nucl Med. 2019;60(5):608–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26(8):905–13.

Article  CAS  PubMed  Google Scholar 

Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, et al. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in patients with metastatic ER + breast Cancer undergoing treatment with Rintodestrant. Clin Cancer Res. 2023;29(11):2075–84.

Article  CAS  PubMed  Google Scholar 

van Geel JJL, Boers J, Elias SG, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, Kuip EJM, Jager A. Menke-Van Der Houven Van Oordt WC et al: clinical validity of 16α-[. J Clin Oncol. 2022;40(31):3642–52.

PubMed  Google Scholar 

National Cancer Institute. Cancer statistics. Reports on Cancer. 2022. https://seer.cancer.gov/statfacts/html/breast-subtypes.html

Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy MP, D’Hondt V, et al. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol. 2021;13:1758835920987657.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, et al. Triple positive early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget. 2016;7(14):17932–44.

Article  PubMed  PubMed Central